Nav: Home

Announcing the inaugural online immuno-oncology symposium

March 28, 2017

Oncology Central is delighted to be hosting, "Practical clinical aspects of immuno-oncology" a 2-day online symposium exploring the latest developments in cancer immunotherapy, chaired by Professor Angus Dalgleish (St George's, University of London).

Immunotherapy is a huge and still-emerging area within oncology, which is having a significant impact on the way patients with certain malignancies are being treated. This year, the American Society of Clinical Oncology (ASCO) named cancer immunotherapy as their clinical cancer Advance of the Year for a second consecutive year, highlighting its continuing importance in changing the face of cancer care.

At the end of June, Oncology Central is hosting a free 2-day online educational symposium, chaired by Professor Angus Dalgleish (St George's, University of London) delivering a series of talks and discussions by leading experts in the field, aiming to review the current status of immunotherapy in the clinic.

This event will be delivered on a highly interactive platform, and will offer delegates a unique opportunity to further explore recent trends and data in the field of cancer immunotherapy, as well as the opportunity to discuss and debate how these may impact everyday practice. Our experts will present on key areas such as rational combinations of immunotherapies with other therapies and management of therapy-related toxicities, as well as looking at optimization of these therapies and discussing the need for better biomarkers of response.

"As immunotherapy continues to make waves within oncology, we are excited to be able to offer this unique, fully online event in collaboration with some of the leading experts in the field," commented Jade Parker, Editor of Oncology Central. "Our encompassing programme aims to deliver a well-rounded update on the impact these therapies have had in the clinic thus far and to look to the future of the field."

Speakers already confirmed include Roy Herbst of Yale School of Medicine (CT, USA) and Hossein Borghaei of Fox Chase Cancer Center (PA, USA), with more to be announced soon.

This online symposium will be certified for CME credit. To find out more and to register for this free event, please click here:
About Oncology Central

Oncology is a fast-moving, multidisciplinary field at the forefront of medical research. At Oncology Central, the online resource powered by Future Science Group, we unite all aspects of oncology to support synergistic progression in the field through collaboration and learning.

Designed exclusively for medical professionals, and endorsed by an expanding board of expert Ambassadors from across the globe, we deliver high-quality and relevant content in an accessible and innovative way. Every day we aim to help you stay up to date with the latest developments in cancer research by providing the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content that can be digested quickly and easily.

Find out more:

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

Future Science Group

Related Immunotherapy Articles:

Algorithm personalizes which cancer mutations are best targets for immunotherapy
As tumor cells multiply, they often spawn tens of thousands of genetic mutations.
Tasmanian devil research could help tackle immunotherapy resistance
A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumours, may give clues to how cancers evade the immune system, according to a study part-funded by Cancer Research UK and published in Cancer Cell today (Thursday).
B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.
Delivering immunotherapy directly to brain tumors
A new study published this week gives insight into how cancer immunotherapies might one day be delivered directly to the brain in order to treat brain tumors.
Researchers discover a new form of immunotherapy
A new form of immunotherapy that has so far been tested on mice makes it probable, that oncologists in the future may be able to treat some of the patients who are not responding to existing types of immunotherapy.
More Immunotherapy News and Immunotherapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...